EAS 2022 "According to [these] data, there is no reason why you should give aspirin to an individual with high Lp(a)," says prof. Catapano. He recapitulates the findings of a study by Olmastroni and colleagues.
EAS 2022 It is recommended that risk factors, such as LDL-c, should be controlled in patients with high Lp(a) levels. Prof. Catapano briefly summarizes the findings of a study on this topic that was presented at EAS 2022.
EAS 2022 Thus far there is no effective therapy to reduce Lp(a) levels. Risk factor modification is recommended for persons with high Lp(a), but how much LDL-c lowering is needed to overcome the increased ASCVD risk caused by high Lp(a)?
EAS 2022 A study found that Lp(a) is not associated with VTE and the increased risk of MI caused by high Lp(a) levels is unlikely to be decreased by antiplatelet or antithrombin therapy.
Lp(a) levels are thought to stay stable over time, at least in adults. As several lipid values change during childhood, Lp(a) values were measured in a large cohort of children. The result: Lp(a) levels increased with age.
The combination of high Lp(a) levels and high BMI conferred a 3.5-fold risk of CAVD compared with both risk factors in the bottom 50%. Absolute 10-year risk of CAVD was higher in men than in women and increased with higher age, Lp(a) and BMI.
ACC 2022 A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we are going to be able to treat this disorder”, Nissen said.
ACC 2022 A phase 1 single ascending dose study showed that subcutaneous injection of SLN360, an siRNA targeting mRNA for the LPA gene, lowered Lp(a) up to 98% in adults with elevated Lp(a) levels.
A study shows that elevated Lp(a) is independently associated with accelerated progression of low-attenuation plaque in patients with advanced multivessel CAD on guideline-directed preventive therapies.
Achieving LDL-c target, measurements of risk factors, and a need for tailored therapy choices are three important factors to reduce (residual) CV risk. Prof. Stroes briefly discusses these three topics.
A case-control study in the Netherlands found an almost 3-fold increased CVD risk in those with very high Lp(a) levels. Addition of Lp(a) to risk scores for patients with very high Lp(a) levels resulted in a higher percentage of patients being reclassified.
In this e-learning program, three experts explain why it is important to measure Lp(a) levels. Furthermore, they describe the effects of currently available lipid-lowering treatments on Lp(a) levels and talk about potential therapies for Lp(a) lowering which are currently under investigation.